BodyComp Analysis
Comprehensive point-of-care body composition analysis beyond BMI
Software · Cloud SaaSCompany source
Company profile
About ImpediMed
ImpediMed is a medical technology company specializing in bioimpedance spectroscopy (BIS) devices for non-invasive measurement of fluid status and tissue composition in both healthy and unhealthy patient populations. The company's flagship SOZO Digital Health Platform is the only FDA-cleared BIS technology that measures 256 frequencies in a single 30-second scan, separating intra- and extracellular fluid for accurate whole-body composition profiling. ImpediMed serves multiple healthcare specialties including cancer survivorship, heart health management, medical weight management, and wellness. The platform enables early detection of lymphedema in cancer patients, monitors fluid changes in heart failure patients, tracks muscle mass loss during GLP-1 therapy, and provides comprehensive body composition analysis. With cloud-connected capabilities through MySOZO, the platform delivers actionable data at the point of care with integrated EHR compatibility, enabling personalized, coordinated care across the patient treatment journey. The company's solutions include L-Dex Analysis for lymphedema, BodyComp Analysis for body composition, Segmental BodyComp Analysis for limb-specific measurements, and HF-Dex Analysis for heart failure fluid assessment. ImpediMed's technology is designed for seamless clinical workflow integration, providing clear reporting with thresholds, historical data, and longitudinal tracking to support informed clinical decision-making.
Company description ImpediMed official website
Primary marketRemote Patient Monitoring & Wearables
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at ImpediMed?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Body composition disorders
- Cancer survivorship complications
- Fluid overload
- Heart failure
- Lymphedema
- Muscle mass loss during GLP-1 therapy
- Obesity
Who it serves
- Cancer Centers
- Cardiology Practices
- Health Systems
- Oncology Practices
- Weight Management Clinics
- Wellness Centers
Deployment & integration
Cloud Saas · Hybrid deployment with recorded integration context.
Recorded integration context: Auto-documentation capabilities, Leading EHR systems.
Geographic context
MarketsUnited States
Company sourceOfficial website
Company milestones
Platform expansion
Erik Anderson appointed as Chief Executive Officer (April 2026), Erik Anderson appointed to Board of Directors (February 2026), Broadened breast cancer survivorship monitoring at ASBrS 2026 (May 2026)
Partnerships
Recorded partners
- NAPBC (National Accreditation Program for Breast Centers)
- NCCN (National Comprehensive Cancer Network)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
HF-Dex Analysis for Heart Failure
Point-of-care heart failure fluid assessment technology beyond the scale
Software · Cloud SaaSCompany source
L-Dex Analysis for Lymphedema
Leading point-of-care technology for lymphedema assessment and early detection
Software · Cloud SaaSCompany source
MySOZO
HIPAA-compliant cloud platform for coordinated patient care and data access
Platform · Cloud SaaSCompany source
Segmental BodyComp Analysis
Advanced point-of-care segmental body composition analysis for arms and legs
Software · Cloud SaaSCompany source
SOZO Digital Health Platform
FDA-cleared bioimpedance spectroscopy platform for non-invasive fluid status and tissue composition monitoring
Device · HybridCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Axillary Treatment and Chronic Breast Cancer-Related Lymphedema: Implications for Prospective Surveillance and Intervention From a Randomized Controlled Trial.JCO oncology practice · Dec 1, 2023
Clinical Utility of Fluid Volume Assessment in Heart Failure Patients Using Bioimpedance Spectroscopy.Frontiers in cardiovascular medicine · Jan 1, 2021
Agreement between supine and standing bioimpedance spectroscopy devices and dual-energy X-ray absorptiometry for body composition determination.Clinical physiology and functional imaging · Sep 1, 2019
The attention-enhancing effects of spearmint extract supplementation in healthy men and women: a randomized, double-blind, placebo-controlled, parallel trial.Nutrition research (New York, N.Y.) · Apr 1, 2019
Muscle fiber hypertrophy in response to 6 weeks of high-volume resistance training in trained young men is largely attributed to sarcoplasmic hypertrophy.PloS one · Jan 1, 2019
Pre-training Skeletal Muscle Fiber Size and Predominant Fiber Type Best Predict Hypertrophic Responses to 6 Weeks of Resistance Training in Previously Trained Young Men.Frontiers in physiology · Jan 1, 2019
Clinical validation
Clinical-trial records
Prehabilitation With Aerobic and Resistance Exercise for Improving Physical Fitness and Quality of Life Outcomes in Older Patients Undergoing CAR-T Therapy for Relapsed or Refractory Multiple MyelomaNCT07045727 · Mentioned · TERMINATED
Almonds, Gut Microbiome and KidsNCT07636850 · Mentioned · RECRUITING
Evaluating Metabolic Health in Individuals With Extreme ObesityNCT07613255 · Mentioned · NOT YET RECRUITING
Lymphedema Surveillance StudyNCT02743858 · Mentioned · RECRUITING
INFANT HEALTH- Promoting Mental Health and Healthy Weight in Infancy Through Sensitive ParentingNCT04601779 · Mentioned · COMPLETED
Effect of Lentils and Chickpeas on Gut Microbiome and Metabolic HealthNCT06914375 · Mentioned · ACTIVE NOT RECRUITING
Regulatory
Regulatory records
SOZOK190529 · 510k · Nov 25, 2019
SOZOK180126 · 510k · Apr 16, 2018
SOZOK172507 · 510k · Dec 22, 2017
SOZOK172122 · 510k · Aug 11, 2017
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Up to 58% of cancer patients at risk for lymphedema
Early detection enables prevention of progression to chronic condition
20% muscle mass loss with GLP-1 therapy
Monitoring during rapid weight reduction
30-second scan time
Fast, non-invasive measurement with immediate results
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Erik Anderson
Chief Executive Officer
06 · Company updates
Updates from ImpediMed
Recent articles published on ImpediMed's official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Remote Patient Monitoring & Wearables
Companies providing AI-powered remote patient monitoring solutions, wearable health devices with AI analytics, continuous health tracking, or platforms that monitor patients outside clinical settings. Includes general wellness wearables with AI coaching, respiratory monitoring devices, and connected health platforms that aggregate and analyze physiological data from sensors.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.